EPISODE · Aug 2, 2024 · 18 MIN
Gilles Salles, MD, PhD - Differentiating Decisions in Transplant-Ineligible Relapsed/Refractory DLBCL: What Are Our Options, and How Do We Choose Between Them?
from PeerVoice Internal Medicine Audio · host PeerVoice
Gilles Salles, MD, PhD - Differentiating Decisions in Transplant-Ineligible Relapsed/Refractory DLBCL: What Are Our Options, and How Do We Choose Between Them?
What this episode covers
Visit https://www.peervoice.com/DDU860 to view the entire programme with slides. After completing “Gilles Salles, MD, PhD - Differentiating Decisions in Transplant-Ineligible Relapsed/Refractory DLBCL: What Are Our Options, and How Do We Choose Between Them?”, participants will be able to: Assess clinical trial data evaluating approved therapies in the management of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), including chemotherapy, immunotherapy, and CAR T-cell therapy; and Formulate individualised treatment plans for patients with DLBCL upon progression to relapsed/refractory disease who are ineligible for stem-cell transplantation.
NOW PLAYING
Gilles Salles, MD, PhD - Differentiating Decisions in Transplant-Ineligible Relapsed/Refractory DLBCL: What Are Our Options, and How Do We Choose Between Them?
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Feb 8, 2026 ·4m
Jan 30, 2026 ·6m
Jan 2, 2026 ·47m